VF
ABCL icon

Virtu Financial’s AbCellera Biologics ABCL Stock Holding History

Virtu Financial’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-181,031
Closed -$619K – 1562
2025
Q4 		$619K Buy
+181,031
New +$808K 0.02% 514
2025
Q3 		– Sell
-206,710
Closed -$709K – 1408
2025
Q2 		$709K Buy
206,710
+183,341
+785% +$456K 0.04% 449
2025
Q1 		$52K Buy
+23,369
New +$67K ﹤0.01% 1005
2024
Q3 		– Sell
-14,604
Closed -$43K – 1302
2024
Q2 		$43K Buy
+14,604
New +$55.3K ﹤0.01% 923
2023
Q3 		– Sell
-30,276
Closed -$196K – 1211
2023
Q2 		$196K Buy
+30,276
New +$207K 0.02% 822
2023
Q1 		– Sell
-32,598
Closed -$330K – 1469
2022
Q4 		$330K Buy
32,598
+17,548
+117% +$203K 0.04% 446
2022
Q3 		$149K Buy
+15,050
New +$165K 0.01% 975

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Virtu Financial's ABCL Position: Q1 2026 in Review

Virtu Financial sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 181,031 shares — an estimated $619K sold.

Virtu Financial first reported a position in ABCL in Q3 2022 and held it in 7 quarters. The position peaked at $709K in Q2 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Virtu Financial reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 181,031 AbCellera Biologics shares in Q1 2026, an estimated $619K.
  • Virtu Financial first reported a position in AbCellera Biologics in Q3 2022 and held it in 7 quarters.
  • Virtu Financial's AbCellera Biologics position peaked at $709K in Q2 2025.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.